Harpoon Therapeutics Inc (HARP)

NASDAQ
9.86
-0.41(-3.99%)
After Hours
9.85
-0.01(-0.10%)
- Real-time Data
  • Volume:
    667,436
  • Bid/Ask:
    9.69/10.10
  • Day's Range:
    9.56 - 10.27

HARP Overview

Prev. Close
9.86
Day's Range
9.56-10.27
Revenue
23.15M
Open
10.26
52 wk Range
9.56-25.24
EPS
-3.44
Volume
667,436
Market Cap
320.68M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
453,624
P/E Ratio
-
Beta
-
1-Year Change
-18.11%
Shares Outstanding
32,523,801
Next Earnings Date
Aug 10, 2021
What is your sentiment on Harpoon Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Harpoon Therapeutics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellSell
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellStrong Sell
SummaryStrong BuyBuyStrong SellStrong SellStrong Sell

Harpoon Therapeutics Inc Company Profile

Harpoon Therapeutics Inc Company Profile

Employees
84

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Read More
  • Back to 21
    0
    • Harpoon to da moon
      0
      • wow exploded suddenly. awesome
        0
        • It’s a buy now, tremendous upside🤑
          0
          • These guys focus in T cells which is needed for a COVID vaccine, I wonder why these guys are selling off so hard?
            0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.